ADEM: A Current Look at How the Brain Comes Under Immune Attack and What It Means for Patients
Acute disseminated encephalomyelitis, most often referred to as ADEM, is a rare inflammatory condition that causes sudden, widespread swelling throughout the brain and spinal cord. While the name sounds alarming, ADEM most often affects children and young adults, and many people do recover fully when treatment begins promptly. Still, navigating a new ADEM diagnosis can feel overwhelming, particularly because the condition can closely resemble other neurological diseases and because establishing a clear diagnosis requires careful evaluation.
A comprehensive review published in Brain Sciences in early 2026 offers an updated look at what researchers now understand about how ADEM develops, how it presents, and where the science currently stands. The review drew on a literature search conducted between late 2024 and mid-2025 and incorporates the most current research available on ADEM's underlying mechanisms and clinical features.
ADEM occurs when the immune system launches an inflammatory attack on the myelin sheath, the protective coating around nerve fibers in the central nervous system. This typically follows a trigger, most often a viral or bacterial infection, though it occasionally occurs after vaccination. Researchers believe the immune system, while fighting off an infection, mistakenly targets proteins in the brain and spinal cord that share structural similarities with the pathogen. This process, called molecular mimicry, is thought to be a key driver of the condition.
The condition typically presents with a sudden onset of neurological symptoms including fever, headache, confusion, seizures, and problems with movement or coordination. In children, these symptoms generally appear one to three weeks after a preceding illness. MRI imaging plays a central role in diagnosis, typically revealing characteristic patterns of inflammation affecting multiple areas of the brain and spinal cord at the same time, a feature that helps distinguish ADEM from conditions like multiple sclerosis.
Treatment focuses on rapidly reducing inflammation. High-dose intravenous corticosteroids remain the standard first-line approach, and most patients begin improving within days. For those who do not respond adequately, intravenous immunoglobulin or plasma exchange may be used. The review highlights a critical gap: no randomized controlled trials have been conducted to formally compare treatment approaches in ADEM, meaning current care is based on observational data and expert consensus rather than definitive clinical evidence. The authors identify this as an important priority for future research. While most people with ADEM recover substantially, long-term follow-up matters, as some patients with more severe episodes may experience lasting cognitive difficulties, motor deficits, or seizures, and understanding these outcomes is part of providing patients and families with genuinely supportive care.